Wearable injectors, which have been made to allow the delivery of large volumes of medication under the skin over a period of time, are becoming popular because of their numerous advantages. These are, among others: the increasing prevalence of chronic diseases, the rising need for drug administration at home and a patient-friendly approach, the use of biologics, technological advancements, and the desire to lower the healthcare costs and needle-stick injuries.
Key Growth Drivers and Opportunities
Rising Prevalence of Chronic Diseases: The rising incidence of chronic conditions such as diabetes, cancer, and autoimmune disorders is a significant factor in the increasing need for wearable injectors, which provide a simple, less expensive, and patient-friendly solution to standard hospital infusions that are compatible with the trend towards self-administration at home, safe and easy care.
Challenges
Limitations that are faced by the wearable injectors market include the high cost of devices, difficulties in managing large or highly viscous drugs, stringent regulatory requirements, the possibility of device failures or skin irritation and the low level of patient awareness or training requirements which may act as barriers to the wider use of the market though having solid growth potential.
Innovation and Expansion
BD Announced First Pharma-Sponsored Clinical Trial
In July 2025, BD, a worldwide medical technology firm, has announced the first pharma-sponsored combination product clinical study employing the BD Libertas Wearable Injector for subcutaneous administration of complex biologics.
The BD Libertas Wearable Injector was chosen for this pharma-sponsored trial after successful outcomes from over 50 BD-conducted pre-clinical and clinical studies. The device clinical study demonstrated excellent performance, with 100% of study participants stating they would likely use the BD Libertas Wearable Injector if prescribed.
Datwyler Introduced NeoFlex Plungers for Large-Volume Biologics in Auto and Wearable Injectors
In October 2024, Datwyler has announced that their NeoFlex coated plunger line would be expanded with additional container sizes for large-volume auto-injectors and wearable devices. At CPHI Worldwide in Milan, Italy (Booth 20B48), the business introduced its NeoFlex Prefilled Syringe 10 ml and NeoFlex Cartridge Wearable 10 mL. The new plungers are designed to satisfy the greatest quality and safety requirements, and they can handle the particular challenges of delivering huge volumes of injectables through these devices.
The use of auto- and wearable injectors is increasing, spurred by the acceptance of at-home treatment for chronic conditions. These devices enable the self-administered therapy of some malignancies, as well as autoimmune, neurological, and cardiovascular illnesses, using large volume subcutaneous biopharmaceuticals (LVSCs).
Inventive Sparks, Expanding Markets
The innovators of wearables injectors plan, as a matter of top priority, such essential things as innovation, partnering with pharmaceutical companies, digital integration, geographical expansion, and economical manufacturing to create lasting success.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.
